|  |  |  |  |
| --- | --- | --- | --- |
| **Supplementary** **Table 2.** Summary of all-causality TEAEs through week 80 (treatment + follow-up period) | | | |
| **N (%) of patients** | **Tanezumab**  **5 mg**  **(n = 92)** | **Tanezumab**  **10 mg**  **(n = 93)** | **Celecoxib**  **200 mg**  **(n = 92)** |
| Any TEAE | 70 (76.1) | 63 (67.7) | 67 (72.8) |
| Serious TEAE | 8 (8.7) | 11 (11.8) | 4 (4.3) |
| Severe TEAE | 3 (3.3) | 2 (2.2) | 2 (2.2) |
| Treatment discontinuation due to TEAE | 3 (3.3) | 5 (5.4) | 4 (4.3) |
| Study discontinuation due to TEAE | 1 (1.1) | 1 (1.1) | 0 |
| Most common TEAEs\*  Nasopharyngitis  Back pain  Fall  Contusion  Arthralgia  Intervertebral disc protrusion  Headache  Hypoesthesia  Pain in extremity  Myalgia  Pyrexia  Diarrhea  Gastroenteritis  Musculoskeletal pain  Pneumonia  Hypertension  Constipation  Influenza  Ligament sprain  Arthritis  Periarthritis  Dizziness  Rash | 19 (20.7)  7 (7.6)  7 (7.6)  5 (5.4)  11 (12.0)  2 (2.2)  3 (3.3)  6 (6.5)  5 (5.4)  3 (3.3)  2 (2.2)  2 (2.2)  2 (2.2)  3 (3.3)  3 (3.3)  2 (2.2)  1 (1.1)  1 (1.1)  3 (3.3)  0  6 (6.5)  2 (2.2)  3 (3.3) | 19 (20.4)  7 (7.5)  6 (6.5)  5 (5.4)  5 (5.4)  3 (3.2)  4 (4.3)  3 (3.2)  2 (2.2)  1 (1.1)  2 (2.2)  1 (1.1)  1 (1.1)  1 (1.1)  0  0  3 (3.2)  3 (3.2)  3 (3.2)  3 (3.2)  1 (1.1)  1 (1.1)  0 | 11 (12.0)  9 (9.8)  5 (5.4)  3 (3.3)  7 (7.6)  3 (3.3)  4 (4.3)  5 (5.4)  4 (4.3)  1 (1.1)  5 (5.4)  3 (3.3)  3 (3.3)  4 (4.3)  1 (1.1)  4 (4.3)  1 (1.1)  2 (2.2)  4 (4.3)  1 (1.1)  0  4 (4.3)  3 (3.3) |
| \*Reported in ≥ 3% of patients in any treatment group. TEAE = treatment-emergent adverse event. | | | |